Brii Biosciences Limited (BRIBF)
USD 0.18
(46.03%)
USD 0.18
(46.03%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 3.15 Million CNY | -75.06% |
| 2022 | 12.65 Million CNY | -41.45% |
| 2021 | 21.61 Million CNY | -23.69% |
| 2020 | 28.32 Million CNY | -19.33% |
| 2019 | 35.11 Million CNY | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | - CNY | -100.0% |
| 2024 Q2 | - CNY | 0.0% |
| 2023 Q2 | 7.99 Million CNY | 0.0% |
| 2023 FY | 3.15 Million CNY | -75.06% |
| 2023 Q4 | 3.15 Million CNY | 0.0% |
| 2023 Q1 | - CNY | -100.0% |
| 2023 Q3 | - CNY | -100.0% |
| 2022 Q1 | 8.2 Million CNY | -62.05% |
| 2022 FY | 12.65 Million CNY | -41.45% |
| 2022 Q4 | 12.65 Million CNY | 301.01% |
| 2022 Q3 | 3.15 Million CNY | -81.94% |
| 2022 Q2 | 17.47 Million CNY | 112.96% |
| 2021 Q1 | 6.14 Billion CNY | 21587.23% |
| 2021 FY | 21.61 Million CNY | -23.69% |
| 2021 Q2 | 27.41 Million CNY | -99.55% |
| 2021 Q3 | 12.64 Million CNY | -53.86% |
| 2021 Q4 | 21.61 Million CNY | 70.92% |
| 2020 Q1 | - CNY | 0.0% |
| 2020 FY | 28.32 Million CNY | -19.33% |
| 2020 Q4 | 28.32 Million CNY | -98.83% |
| 2020 Q3 | 2.42 Billion CNY | 0.0% |
| 2019 FY | 35.11 Million CNY | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Capstone Therapeutics Corp. | 20.32 Million USD | 84.475% |
| Skye Bioscience, Inc. | 4.61 Million USD | 31.618% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 89.398% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -2476.327% |
| Qrons Inc. | 351.84 Thousand USD | -796.981% |
| Adynxx, Inc. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 4.71 Million USD | 33.014% |
| CSL Limited | 12.18 Billion USD | 99.974% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 92.724% |
| Arch Therapeutics, Inc. | 5.87 Million USD | 46.245% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -317.348% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 93.073% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Rebus Holdings, Inc. | 310 Thousand USD | -918.065% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -400.891% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -12171.084% |
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 92.34% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | 23.434% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -685.37% |
| SQZ Biotechnologies Company | 27.47 Million USD | 88.512% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | -35.686% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -232.816% |
| Mesoblast Limited | 118.7 Million USD | 97.341% |
| Marizyme, Inc. | 18.71 Million USD | 83.139% |
| Genus plc | 233.1 Million USD | 98.646% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | -7.699% |
| Pharming Group N.V. | 171.54 Million USD | 98.16% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -255.38% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -134.894% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -320.8% |
| ContraFect Corporation | 2.88 Million USD | -9.545% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -2229.375% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | -118.209% |
| IMV Inc. | 28.88 Million USD | 89.073% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | 44.224% |
| MultiCell Technologies, Inc. | 202.58 USD | -1557803.051% |
| ONE Bio Corp. | 19.71 Million USD | 83.992% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 94.51% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.49 Million USD | -111.139% |
| Q BioMed Inc. | 4.1 Million USD | 23.211% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 90.466% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -156.928% |
| Biomind Labs Inc. | 735.54 Thousand USD | -329.071% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 95.334% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | -4.29% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 75.717% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -777.373% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -2130.105% |
| Curative Biotechnology, Inc. | 2.25 Million USD | -39.746% |
| GB Sciences, Inc. | 1.75 Million USD | -79.389% |
| Alpha Cognition Inc. | 1.22 Million USD | -158.61% |
| HST Global, Inc. | 98.31 Thousand USD | -3109.959% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -1168.897% |
| Halberd Corporation | 150 Thousand USD | -2004.0% |
| Enzolytics Inc. | 996.33 Thousand USD | -216.76% |
| Agentix Corp. | 50 Thousand USD | -6212.0% |
| Resverlogix Corp. | 6.49 Million USD | 51.379% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -1134.78% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 20 Million USD | 84.22% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 55.378% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -16.513% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -30765.526% |
| Genscript Biotech Corporation | 417.73 Million USD | 99.245% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -1473.155% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | -31.625% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -1276.417% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -2023.051% |
| Kadimastem Ltd | 891.22 Thousand USD | -254.119% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -1161.482% |
| LadRx Corporation | 33.6 Thousand USD | -9291.18% |
| Cell Source, Inc. | 9.25 Million USD | 65.896% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -317.348% |
| NovAccess Global Inc. | 2.19 Million USD | -43.462% |
| Affymax, Inc. | - USD | -Infinity% |
| Itoco Inc. | 228.37 Thousand USD | -1281.926% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -1395.912% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | 36.665% |
| Mobile Lads Corp. | 484.28 Thousand USD | -551.684% |
| CytoDyn Inc. | 30.07 Million USD | 89.507% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | 59.642% |
| SYBLEU INC | 477.5 Thousand USD | -560.942% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | 33.351% |
| International Stem Cell Corporation | 4.17 Million USD | 24.461% |
| Bioxytran, Inc. | 1.92 Million USD | -63.948% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -4956.639% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -44.711% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | 62.049% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | 63.238% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | -102.896% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -1077.612% |
| Neutra Corp. | 54.15 Thousand USD | -5727.609% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | -72.459% |
| PureTech Health plc | 25.51 Million USD | 87.629% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -157.796% |
| IXICO plc | 472.02 Thousand USD | -568.611% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 79.64% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 94.931% |
| CSL Limited | 12.18 Billion USD | 99.974% |
| Cellectis S.A. | 92.77 Million USD | 96.598% |